NTQ1062
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for NTQ1062, covering 2024-07-29 to 2026-02-06. Get the full timeline:
Most recent: Clinical Trial Update: A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer [Phase 3]